Form 4: STERIS plc VP & CAO Karen L. Burton Reports Sale of Ordinary Shares

Karen L. Burton, VP & CAO of STERIS plc, reported the sale of 3,000 ordinary shares at a price of $235.95 on May 14, 2024, leaving her with 3,759 shares.

Summary

• On May 14, 2024, Karen L. Burton, VP & CAO of STERIS plc, sold 3,000 ordinary shares of the company.
• The sale price was $235.95 per share.
• Following the transaction, Burton directly owns 3,759 ordinary shares.
• 2,457 of these shares are restricted and will lapse at various dates between May 31, 2024, and June 2, 2026.

Sentiment

Score: 5

Explanation: The document is a neutral report of an insider transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider trading activity. It's common for executives to periodically sell shares for personal financial management.

Comparison to Industry Standards

• Executive stock sales are a normal part of compensation and portfolio management across publicly traded companies.
• Comparing Burton's transactions to those of executives at similar medical equipment and services companies like Medtronic or Boston Scientific would provide context on the scale and frequency of such sales.
• Reviewing insider trading reports for these companies on the SEC's EDGAR database can offer benchmarks for executive stock transactions.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders if they interpret it as a lack of confidence in the company's future, although such sales are often part of personal financial planning.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal, as this is a routine transaction.

Key Dates